Section Arrow
PFSA.NASDAQ
- Profusa Inc.
(Financial Status)
Quotes are at least 15-min delayed:2026/08/05 19:37 EDT
After Hours
Last
 0.9242
-0.0167 (-1.77%)
Bid
0.9244
Ask
0.96
High 0.9688 
Low 0.922 
Volume 4.18K 
Regular Hours (Closed)
Last
 0.9409
-0.0391 (-3.99%)
Day High 
0.962 
Prev. Close
0.98 
1-M High
3.01 
Volume 
67.41K 
Bid
0.9244
Ask
0.96
Day Low
0.892 
Open
0.96 
1-M Low
0.8608 
Market Cap 
519.40K 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.27 
20-SMA 1.67 
50-SMA 4.13 
52-W High 1,297.5 
52-W Low 0.8608 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-384.07/--
Enterprise Value
8.40M
Balance Sheet
Book Value Per Share
-53.20
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
BJDXBluejay Diagnostics Inc.1.24+0.24+24.00%-- 
After Hours 1.25 +0.01 +0.81%
BSXBoston Scientific Corp47.74-1.35-2.75%20.57PE
After Hours 48.7 +0.96 +2.01%
AMIXAutonomix Medical Inc.12.1-7.4-37.95%-- 
After Hours 12.1 0 0.00%
ADGMAdagio Medical Holdings Inc.0.739-0.061-7.63%-- 
After Hours 0.7106 -0.0284 -3.84%
PACBPacific Biosciences of California1.3-0.14-9.72%-- 
After Hours 1.2902 -0.0098 -0.75%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.